Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03305081 · ClinicalTrials.gov registry record · NA
Patient Compliance With Long-Acting Reversible Contraception Administration
A NA study, sponsored by Tulane University School of Medicine.
- Terminated
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT03305081: Clinical Trial NA study, sponsored by Tulane University School of Medicine.
NCT03305081 is a NA study that was terminated before completion, run by Tulane University School of Medicine. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03305081, a NA study, was terminated before completion, sponsored by Tulane University School of Medicine.
- TERMINATED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
This a randomized control trial to identify if patients who desire LARC are more likely to have success receiving the desired form of contraception if it is placed a) during the postpartum hospital stay, either in the immediate or early postpartum period, versus b) during the interval postpartum period as previously done.
Primary Outcome
The outcome will be measured by the number of participants with LARC placement. The total number of women who expressed a desire to have postpartum contraception placed and randomized to the appropriate arm will be assessed.
Interventions
- DEVICE Levonorgestrel IUD, copper IUD, etonorgestrel implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-10-22 |
| Est. Completion | 2016-05-31 |
| Phase | NA |
Why NCT03305081 stopped before completion
NCT03305081 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Levonorgestrel IUD, copper IUD, etonorgestrel implant is the first listed.
NCT03305081 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03305081 about?
NCT03305081 is a clinical study titled "Patient Compliance With Long-Acting Reversible Contraception Administration". This a randomized control trial to identify if patients who desire LARC are more likely to have success receiving the desired form of contraception if it is placed a) during the postpartum hospital stay, either in the immediate or early postpartum period, versus b) during the interval postpartum per...
What is the current status of trial NCT03305081?
This trial is currently terminated. It is a NA study. The enrollment target is 45 participants. The study started on 2014-10-22. Estimated completion is 2016-05-31.
What interventions are being tested in trial NCT03305081?
The interventions under investigation include: Levonorgestrel IUD, copper IUD, etonorgestrel implant (DEVICE).
Who is sponsoring clinical trial NCT03305081?
This trial is sponsored by Tulane University School of Medicine, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03305081's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI